Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 20;6:e2100330. doi: 10.1200/PO.21.00330

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — ERBB2 CN as a predictor of rwPFS in patients with advanced GEA treated with anti-HER2 therapy in the first-line setting. Association of ERBB2 CN with rwPFS in patients with GEA treated with first-line trastuzumab in the CGDB. ERBB2 CN was predictive as a continuous variable, and no single CN cutoff was identified as an optimal predictor of rwPFS. To visualize Kaplan-Meier rwPFS curves, the cohort was split into ERBB2 CN quintiles. Curves are truncated at 30 months as the number at risk was reduced to one in the entire ERBB2amp cohort. Median and IQR rwPFS for each CN quintile is shown. CGDB, clinicogenomic database; CN, copy number; GEA, gastroesophageal adenocarcinoma; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; rwPFS, real-world progression-free survival.